
EXEL vs MRNA
$EXEL vs $MRNA head to head: price, market cap, valuation, dividend, free float, relative volume and how actively each trades. The bigger value in the size rows is bolded. Tap either ticker for its live chart, full ownership breakdown and real-time alerts.
EXEL vs MRNA: trend, levels and the market
One year to 2026-11-20, against the S&P 500 (+3.2%). Split-adjusted daily closes.
- ·EXEL has the cleaner trend, above both its 50- and 200-day averages, where MRNA is above one and below the other.
- ·Both beat the market over the past year: EXEL +53% and MRNA +707%, against the S&P 500 at +3.2%.
- ·The last month has flipped the order: EXEL has held up better over the month (-1% against -3.8%) even though MRNA leads over the year.
- ·MRNA sits closer to its support, 9.9% above it at $179.56, while EXEL is 10.5% above its own at $56.90.
Support and resistance are daily prices the stock has turned at three or more times, within 35% of the price. The loading zone is the nearby price where the heaviest volume traded. These describe where a stock has been, not where it will go. Not investment advice.
EXEL vs MRNA: the quick read
- ·MRNA is the larger company by market cap ($78.90B vs $15.77B).
- ·MRNA has been more active on our scanner (333 vs 125 alerts in 30 days).
- ·EXEL has the smaller float (226.8M vs 360.3M), which tends to mean sharper, more volatile moves.
- ·Both are biological products, (no diagnostic substances) names, so this is a like-for-like comparison and sector news tends to move them together.
- ·Both stay busy on our scanner, 333 and 125 unusual-volume alerts over 30 days, so neither is the quiet one here.
Objective differences only. Not investment advice.
Watching EXEL or MRNA? Get each morning’s movers by email
Free daily email of the top plays and unusual-volume alerts our scanner flags. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Frequently asked questions
Everything you need to know comparing EXEL and MRNA on TheDesperateTrader.
- Is EXEL or MRNA the better stock?
- "Better" depends on your goal, and these two are not alike. MRNA is the larger company by market cap ($78.90B vs $15.77B). MRNA has been more active on our scanner (333 vs 125 alerts in 30 days). EXEL has the smaller float (226.8M vs 360.3M), which tends to mean sharper, more volatile moves. Those are the measured differences, not a recommendation, and nothing here is investment advice.
- What is the difference between EXEL and MRNA?
- The differences that matter: MRNA is roughly 5x the size of the other by market cap ($15.77B vs $78.90B); they trade at very different share prices ($63.57 vs $199.30); EXEL sits at 70% of its 52-week range against 68% for MRNA; our scanner flagged EXEL 125 times in the last 30 days against 333 for MRNA. Everything above is measured from the latest completed session and SEC filings.
- Which of EXEL and MRNA is more active right now?
- Right now EXEL is at about 0.8x its normal volume and MRNA is at about 0.6x, so EXEL is the one drawing unusual attention today. Relative volume (RVOL) compares a stock's volume to its own recent average, so it reads the same way for a megacap and a microcap and is the quickest way to tell which of two similar names is actually in play.
- Is EXEL or MRNA in the stronger trend?
- EXEL is above its 50-day average of $63.20 and above its 200-day average of $52.86; MRNA is below its 50-day average of $207.89 and above its 200-day average of $100.42. MRNA leads 3 of the 5 measures on this page (1 year, vs S&P 500, 3 months, 1 month, trend). A trend is where a stock has been, not a forecast, and nothing here is investment advice.
- Is this comparison data live?
- Prices and % changes are anchored to the latest completed session and split-adjusted, so a reverse split never shows as a fake move. Float is estimated from SEC filings and refreshed as new filings publish.
Trading EXEL or MRNA? Get real-time unusual-volume alerts the moment either one moves, free.
No card · 5 premium daysMore EXEL and MRNA comparisons
Same sector, similar size. These are the peers each one is usually weighed against.
Explore the market
Free, live market tools. No account required to look.